Treating Portopulmonary Hypertension With Macitentan: Smoking Gun or Magic Bullet?
- 14 May 2020
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in Liver Transplantation
- Vol. 26 (7), 863-865
- https://doi.org/10.1002/lt.25797
Abstract
Portopulmonary hypertension (PPHTN) is detected in about 5% of patients being evaluated for liver transplantation (LT). PPHTN is associated with a 5‐year survival of only 45% in patients receiving medical therapy only. It is crucial to successfully bridge patients to LT by improving pulmonary hemodynamics, increase the number of patients eligible for LT model for end‐stage liver disease (MELD) exception points and avoid waitlist and perioperative mortality. Although there is small observational and retrospective evidence that LT can be safely accomplished with careful patient selection and medical therapy directed at PPHTN, there has not been a lack of randomized and controlled data.Keywords
This publication has 9 references indexed in Scilit:
- Macitentan Improves Risk Categorization for Liver Transplant Mortality in Patients With Portopulmonary Hypertension: A PORTICO Study Post Hoc AnalysisLiver Transplantation, 2020
- Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trialThe Lancet Respiratory Medicine, 2019
- Predictors of Waitlist Mortality in Portopulmonary HypertensionTransplantation, 2017
- Long‐term outcome in liver transplantation candidates with portopulmonary hypertensionHepatology, 2016
- International Liver Transplant Society Practice GuidelinesTransplantation, 2016
- Macitentan and Morbidity and Mortality in Pulmonary Arterial HypertensionThe New England Journal of Medicine, 2013
- Survival in Portopulmonary Hypertension: Mayo Clinic Experience Categorized by Treatment SubgroupsAmerican Journal of Transplantation, 2008
- Portopulmonary hypertension: Results from a 10-year screening algorithmHepatology, 2006
- Pulmonary Hemodynamics and Perioperative Cardiopulmonary-Related Mortality in Patients With Portopulmonary Hypertension Undergoing Liver TransplantationLiver Transplantation, 2000